Prevention of acute graft-versus-host disease in adult T-cell leukemia-lymphoma patients who received mogamulizumab before allogeneic hematopoietic cell transplantation
| Autor: | Masao Matsuoka, Asami Yamada, Yoshitaka Inoue, Miho Matsumoto, Kisato Nosaka, Miho Watanabe, Mikiko Izaki, Masayuki Murai, Nao Nishimura |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Male
medicine.medical_specialty Transplantation Conditioning Graft vs Host Disease Antineoplastic Agents Antibodies Monoclonal Humanized T-Lymphocytes Regulatory Adult T-cell leukemia/lymphoma immune system diseases hemic and lymphatic diseases Internal medicine medicine Mogamulizumab Humans Leukemia-Lymphoma Adult T-Cell Transplantation Homologous Mass cytometry Lymphocyte Count Hematology Hematopoietic cell business.industry Incidence (epidemiology) Hematopoietic Stem Cell Transplantation Patient Acuity hemic and immune systems Middle Aged medicine.disease nervous system diseases Transplantation Graft-versus-host disease nervous system Immunology Acute Disease Female business medicine.drug |
| Zdroj: | International journal of hematology. 115(3) |
| ISSN: | 1865-3774 |
| Popis: | Mogamulizumab (Mog) is effective against adult T-cell leukemia-lymphoma (ATL), but as we reported previously, Mog increases the incidence of severe acute GVHD when administered before allogeneic hematopoietic cell transplantation (allo-HCT). Here, we report the cases of two ATL patients who did not develop acute GVHD despite receiving Mog before allo-HCT. Case 1: a 63-year-old female who underwent allo-HCT from an HLA-matched donor 2 months after the last dose of Mog. Case 2: a 47-year-old male with ATL that relapsed 3 months after first allo-HCT. He received eight doses of Mog and underwent a second allo-HCT from a haploidentical donor 4 months after the last dose of Mog. Mog blood levels were measured and lymphocytes analyzed by mass cytometry. Mog blood levels measured before starting the conditioning regimens were low. A small proportion of regulatory T cells (Tregs) was detected before and shortly after allo-HCT. When using Mog before allo-HCT, it is important to consider the number of Mog doses and the interval from the last dose of Mog to allo-HCT. Analyzing Mog blood levels and Treg counts before and after allo-HCT should also be useful. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink